These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1969668)

  • 21. Characterization of dopamine D-1 and D-2 receptors.
    Hyttel J; Arnt J
    Adv Exp Med Biol; 1986; 204():15-28. PubMed ID: 2878578
    [No Abstract]   [Full Text] [Related]  

  • 22. Enantiomeric analogues of SCH 23390 as new probes for behavioral interactions between D1 and D2 dopaminergic function.
    Waddington JL; Molloy AG; O'Boyle KM; Mashurano M
    Adv Exp Med Biol; 1986; 204():125-36. PubMed ID: 2947424
    [No Abstract]   [Full Text] [Related]  

  • 23. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
    Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
    J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventral striatal dopamine modulation of different forms of behavioral flexibility.
    Haluk DM; Floresco SB
    Neuropsychopharmacology; 2009 Jul; 34(8):2041-52. PubMed ID: 19262467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor signaling and current and future antipsychotic drugs.
    Boyd KN; Mailman RB
    Handb Exp Pharmacol; 2012; (212):53-86. PubMed ID: 23129328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor subtype-specific dopaminergic agents and conditioned behavior.
    Beninger RJ; Hoffman DC; Mazurski EJ
    Neurosci Biobehav Rev; 1989; 13(2-3):113-22. PubMed ID: 2573022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors.
    Morelli M; Fenu S; Di Chiara G
    Life Sci; 1987 Jan; 40(3):245-51. PubMed ID: 2948094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective dopamine D1 and D2 receptor antagonists.
    Hyttel J; Arnt J; van den Berghe M
    Psychopharmacol Ser; 1989; 7():109-22. PubMed ID: 2574447
    [No Abstract]   [Full Text] [Related]  

  • 30. Normal and abnormal determinants of dopamine receptor ontogeny in the central nervous system.
    Feigenbaum JJ; Yanai J
    Prog Neurobiol; 1984; 23(3):191-225. PubMed ID: 6240665
    [No Abstract]   [Full Text] [Related]  

  • 31. The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats.
    Hoffman DC; Beninger RJ
    Pharmacol Biochem Behav; 1985 Feb; 22(2):341-2. PubMed ID: 2858871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathophysiological functions mediated by D1 dopamine receptors.
    Goldstein M; Kuga S; Shimizu Y; Meller E
    Adv Exp Med Biol; 1986; 204():189-95. PubMed ID: 2947428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of prolactin responses to D-1 and D-2 antagonists in rats: Ro 22-1319 is a potent D-2 antagonist.
    Kaneda H; Shintani T; Kakigi T; Terada T; Tanimoto K
    Biol Psychiatry; 1989 Feb; 25(4):517-22. PubMed ID: 2564788
    [No Abstract]   [Full Text] [Related]  

  • 35. Guidance of instrumental behavior under reversal conditions requires dopamine D1 and D2 receptor activation in the orbitofrontal cortex.
    Calaminus C; Hauber W
    Neuroscience; 2008 Jul; 154(4):1195-204. PubMed ID: 18538938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics.
    Delini-Stula A
    Pharmacopsychiatry; 1986 Jul; 19(4):134-9. PubMed ID: 2876445
    [No Abstract]   [Full Text] [Related]  

  • 37. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors.
    Braun AR; Barone P; Chase TN
    Adv Exp Med Biol; 1986; 204():151-66. PubMed ID: 2947426
    [No Abstract]   [Full Text] [Related]  

  • 38. Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P.
    Oblin A; Zivkovic B; Bartholini G
    Eur J Pharmacol; 1984 Oct; 105(1-2):175-7. PubMed ID: 6208042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C; Hall H; Magnusson O; Lewander T; Gustafsson K
    Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential interaction of neuroleptics with apomorphine-induced behavior in rats as a function of changing levels of dopamine receptor stimulation.
    Megens AA; Hendrickx HM; Lavreysen H; Langlois X
    J Pharmacol Exp Ther; 2013 Dec; 347(3):681-96. PubMed ID: 24071734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.